Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis.
Bauersachs R, Wu O, Hawkins N, Bowrin K, Wojciechowski P, Clay E, Huelsebeck M. Bauersachs R, et al. Cardiovasc Ther. 2021 Aug 24;2021:8561350. doi: 10.1155/2021/8561350. eCollection 2021. Cardiovasc Ther. 2021. PMID: 34497668 Free PMC article. Review.
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Weitz JI, et al. Among authors: bauersachs r. N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18. N Engl J Med. 2017. PMID: 28316279 Free article. Clinical Trial.
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Capell WH, et al. Among authors: bauersachs r. Am Heart J. 2018 May;199:83-91. doi: 10.1016/j.ahj.2018.01.011. Epub 2018 Feb 3. Am Heart J. 2018. PMID: 29754671 Clinical Trial.
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.
Prandoni P, Lensing AWA, Prins MH, Gebel M, Pap AF, Homering M, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Cohen AT, Davidson BL, van Bellen B, Verhamme P, Wells PS, Yuan Z, Levitan B, Weitz JI. Prandoni P, et al. Among authors: bauersachs r. Thromb Res. 2018 Aug;168:121-129. doi: 10.1016/j.thromres.2018.06.009. Epub 2018 Jul 10. Thromb Res. 2018. PMID: 30064683
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy.
Pastori D, Eikelboom JW, Anand SS, Patel MR, Tanguay JF, Ricco JB, Debus ES, Mazzolai L, Bauersachs R, Verhamme P, Bosch J, Nikol S, Nehler M, Aboyans V, Violi F. Pastori D, et al. Among authors: bauersachs r. Thromb Haemost. 2019 Apr;119(4):576-585. doi: 10.1055/s-0039-1678527. Epub 2019 Jan 31. Thromb Haemost. 2019. PMID: 30703812 Review.
Rivaroxaban in Peripheral Artery Disease after Revascularization.
Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, Mátyás L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Bonaca MP, et al. Among authors: bauersachs rm. N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. Epub 2020 Mar 28. N Engl J Med. 2020. PMID: 32222135 Clinical Trial.
240 results